CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade
Milotay G. et al, (2025), Nature Medicine
Longitudinal Genomic Analysis to Fine-Tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients With BRAF V600-Mutant Metastatic Melanoma.
Dummer R. et al, (2025), Clin Cancer Res
Tissue-resident natural killer cells support survival in pancreatic cancer through promotion of cDC1-CD8 T activity.
Go S. et al, (2024), Elife, 13
Tissue-resident natural killer cells support survival in pancreatic cancer through promotion of cDC1-CD8 T activity
Go S. et al, (2024), eLife, 13
Validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries: a retrospective, comparative analysis.
Jackson A. et al, (2024), Lancet Oncol, 25, 1476 - 1486
Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial.
Scanlon E. et al, (2024), ESMO Open, 9
A retrospective analysis of the validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries
Jackson A. et al, (2024), The Lancet Oncology
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.
Hamid O. et al, (2024), J Clin Oncol
Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination.
Watson RA. et al, (2024), J Immunother Cancer, 12
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.
Luke JJ. et al, (2024), J Immunother Cancer, 12
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
Larkin J. et al, (2024), Cell Rep Med, 5
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM).
Dayimu A. et al, (2024), Eur J Cancer, 196
A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP).
Starkey T. et al, (2023), Sci Rep, 13
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Carroll TM. et al, (2023), Cancer Cell, 41, 1222 - 1241.e7
Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study.
Nicholson BD. et al, (2023), Lancet Oncol, 24, 733 - 743